Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | HTR6 | P50406 | 3/20 | 0.61 |
| ▸ | HTR7 | P34969 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | UBE2N | P61088 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4478721 | 0.91 | HTR6 (0.67) | LMNAMAPK1HTR6HTR7RAB9A | |
| SCHEMBL682813 | 0.90 | HTR7 (0.62) | LMNAMAPK1HTR6HTR7RAB9A | |
| SCHEMBL684362 | 0.89 | RAB9A (0.71) | LMNAHTR6HTR7RAB9AL3MBTL1 | |
| SCHEMBL683655 | 0.89 | HTR7 (0.77) | LMNAMAPK1HTR6HTR7RAB9A | |
| SCHEMBL683995 | 0.88 | MAPK1 (0.72) | LMNAMAPK1HTR6HTR7L3MBTL1 | |
| SCHEMBL684027 | 0.88 | SMN1; SMN2 (0.60) | LMNAMAPK1HTR6HTR7RAB9A | |
| SCHEMBL683604 | 0.87 | RXFP1 (0.62) | LMNAMAPK1HTR6HTR7RAB9A | |
| SCHEMBL684041 | 0.86 | HTR7 (0.58) | LMNAMAPK1HTR6HTR7RAB9A | |
| SCHEMBL684028 | 0.86 | HTR7 (0.58) | LMNAMAPK1HTR6HTR7RAB9A | |
| SCHEMBL683998 | 0.85 | HTR7 (0.57) | LMNAMAPK1HTR6HTR7RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | LMNA 2155/4885MAPK1 470/4885HTR6 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.